Efficacy: NAMENDA XR 28 mg+AChEI
NAMENDA XR 28 mg+AChEI
A significant improvement in cognition
Combination therapy with NAMENDA XR 28 mg+AChEI* demonstrated
greater improvement in cognition vs placebo+AChEI treatment at 24 weeks, using an
- At endpoint, patients treated with NAMENDA XR 28 mg+AChEI demonstrated
significant improvement vs placebo+AChEI (P<0.001)2
NAMENDA XR 28 mg+AChEI was statistically significantly superior to treatment
with placebo+AChEI at endpoint using an LOCF analysis1,2
- At endpoint, there was a 2.6 unit mean difference between treatment groups on the
- AChEI=acetylcholinesterase inhibitor.
- LOCF=last observation carried forward.
- SIB=Severe Impairment Battery.
- SEM=Standard Error of the Mean.
Review efficacy in global function
with NAMENDA XR 28 mg
Learn about once-daily
dosing with NAMENDA XR
NAMENDA XR (memantine HCl) extended-release Prescribing Information. Cincinnati, OH: Forest Pharmaceuticals, Inc.; 2014.
- Data on file. Forest Laboratories, LLC
- Saxton J, McGonigle KL, Swihart AA, Boller F.
The Severe Impairment Battery. Bury St Edmonds; 1993.